ArticleEMBO reports2002
Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein.
Article in EMBO reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- The Furin Protease Dependence and Antiviral GBP2 Sensitivity of Murine Leukemia Virus Infection Are Determined by the Amino Acid Sequence at the Envelope Glycoprotein Cleavage Site.International journal of molecular sciences · 2024Article
- Directed Molecular Evolution of an Engineered Gammaretroviral Envelope Protein with Dual Receptor Use Shows Stable Maintenance of Both Receptor Specificities.Journal of virology · 2016Article
- Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.Journal of immunology research · 2015Review
- Library screening and receptor-directed targeting of gammaretroviral vectors.Future microbiology · 2013Review
- Construction of a gammaretrovirus with a novel tropism and wild-type replication kinetics capable of using human APJ as entry receptor.Journal of virology · 2012Article
- Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins.Journal of virology · 2012Article
- Retrovirus entry by endocytosis and cathepsin proteases.Advances in virology · 2012Article
- Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations.Journal of virology · 2008Article
- Molecular engineering of viral gene delivery vehicles.Annual review of biomedical engineering · 2008Review
- Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter.Journal of virology · 2006Article
- Murine leukemia virus (MLV) replication monitored with fluorescent proteins.Virology journal · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop a reliable strategy for cell-specific delivery of retroviral vectors, we genetically modified the envelope (Env) protein of the ecotropic Moloney murine leukemia virus. We found a site in the variable region A, where the insertion of ligands, epidermal growth factor (EGF) and stromal-derived factor-1 alpha (SDF-1 alpha), was possible without abolishing virion incorporation of the Env protein and its ecotropic entry function. The vector containing the EGF-Env did not show the EGF receptor-dependent transduction. The vector containing the SDF-1 alpha-Env, however, specifically transduced human cells expressing CXCR4, the receptor for SDF-1 alpha, at titers of 10(3)-10(4) c.f.u./ml. Further experiments showed that the CXCR4-dependent transduction was based on the specific interaction between the SDF-1 alpha moiety of the SDF-1 alpha-Env and CXCR4 and was independent of the ecotropic entry function. The direct targeting of the retroviral vector may be possible if the proper chimeric Env structure and the appropriate ligand-receptor system are employed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.